what is the difference between glp-1 and wegovy Wegovy® Pill Wegovy Pill vs. Foundayo: Which

Fadieienko, N

M., Moore, M., Tronieri, J

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk, has been formulated as Wegovy for obesity treatment and as Ozempic for the management of type 2 diabetes mellitus, utilizing GLP-1 signaling to improve glucose metabolism and promote weight loss.[6] Semaglutide-based drugs are among the most effective weight-loss therapies currently available and are gaining widespread popularity for the treatment of obesity

Retatrutide: The benchmark for weight loss Retatrutide, produced by Eli Lilly, also activates glucagon receptors, alongside GLP-1 receptors and gastric inhibitory polypeptide (GIP) receptors, which helps regulate blood glucose and nutrient balance (leading to the drug being dubbed the triple G for activating these three receptors)

These medications can significantly reduce hunger and caloric intake, leading to substantial weight loss